Statement on extension of TRIPS waiver for COVID-19 diagnostics & therapeutics, 9 January 2023
South Centre Statement on the extension of the TRIPS waiver for diagnostics and therapeutics for COVID-19
Developing countries should consider options that can be implemented now to deal with IP barriers to expand production and access to COVID-19 therapeutics and diagnostics, while the so far elusive decision on whether to extend a TRIPS waiver to cover these products is taken by WTO.
Télécharger (en français):
Descargar (en español):
This article was tagged: Access to Diagnostics, Access to Medicines, Access to Treatments, Access to Vaccines, COVID-19, Diagnostics, Intellectual Property, Pandemic, Public Health, Therapeutics, TRIPS, TRIPS Agreement, TRIPS Waiver, Vaccines, World Trade Organization (WTO), WTO TRIPS Decision on COVID-19 Vaccines